Thrivent Financial for Lutherans Has $85.74 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Thrivent Financial for Lutherans cut its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 7.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,158,750 shares of the medical research company's stock after selling 99,212 shares during the period. Thrivent Financial for Lutherans owned 0.20% of Edwards Lifesciences worth $85,739,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the company. Harbor Capital Advisors Inc. grew its stake in Edwards Lifesciences by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock valued at $824,000 after buying an additional 273 shares during the last quarter. Nordea Investment Management AB grew its stake in Edwards Lifesciences by 34.6% in the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock valued at $301,355,000 after buying an additional 1,043,484 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST grew its stake in Edwards Lifesciences by 6.7% in the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock valued at $355,344,000 after buying an additional 300,000 shares during the last quarter. Sivik Global Healthcare LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at about $3,702,000. Finally, Avanza Fonder AB acquired a new position in Edwards Lifesciences in the 4th quarter valued at about $4,845,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 500 shares of the company's stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company's stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 51,303 shares of company stock worth $3,715,776. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Price Performance

NYSE:EW traded down $0.50 on Friday, hitting $70.46. The company had a trading volume of 7,144,270 shares, compared to its average volume of 4,616,653. The stock has a market capitalization of $41.42 billion, a price-to-earnings ratio of 10.11, a PEG ratio of 4.82 and a beta of 1.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $71.42 and a two-hundred day moving average of $70.37. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on EW. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their price target for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a report on Thursday, February 13th. Evercore ISI cut their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Royal Bank of Canada reissued an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Finally, Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.